FDA opens door to emergency use of convalescent plasma from recovered Covid-19 patients
One potential treatment for Covid-19, known as convalescent plasma, may be derived from patients who have already recovered from the disease, and the FDA said Tuesday that it will help to provide access to it for patients with serious or immediately life-threatening Covid-19 infections.
The idea behind the treatment is that plasma collected from patients recovering from Covid-19 may contain antibodies to the virus that might be effective against the infection. New York Gov. Andrew Cuomo (D) said yesterday that some critically ill patients would be able to access convalescent plasma in some cases.
Although FDA says it’s important to determine, via clinical trials, the safety and effectiveness of convalescent plasma before routinely administering it to patients with COVID-19, the agency said it will allow the use of single patient emergency Investigational New Drug Applications (eINDs) to obtain access to the investigational plasma. Such eINDs can be submitted to FDA via email and the agency says it can provide time-sensitive responses in four to eight hours.
Stephen Hahn
At the White House last week, FDA Commissioner Stephen Hahn said the agency is “really pushing hard to try to accelerate” the use of convalescent plasma. He added: “If you’ve been exposed to coronavirus and you’re better and you don’t have the virus in your blood, we could collect the blood. Now, this is a possible treatment; this is not a proven treatment — just want to emphasize that. Collect the blood, concentrate that, and have the ability, once it’s pathogen-free — that is, virus-free — to be able to give that to other patients. And the immunoglobulins — the immune response — could potentially provide a benefit to patients.”
FDA also says that Covid-19 convalescent plasma must only be collected from recovered individuals (complete resolution of symptoms at least 14 days before a donation) and if they are eligible to donate blood. The required testing must be done, FDA says, while also outlining how it defines what “severe or immediately life-threatening Covid-19” means (see the link at the bottom for more details).
In addition, FDA is working with the National Institutes of Health and the Centers for Disease Control and Prevention to develop master protocols for use by multiple investigators in order to coordinate the collection and use of Covid-19 convalescent plasma.
The use of convalescent plasma was previously studied in other pandemics and epidemics, including the 2009-2010 H1N1 influenza virus pandemic, the 2003 SARS-CoV-1 epidemic, and the 2012 MERS-CoV epidemic, FDA said.
A comment in the Lancet last month said that “several studies showed a shorter hospital stay and lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent plasma.”
Recent PLSH News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 03:28:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 07:24:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/08/2023 08:04:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 05:07:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 01:15:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2023 04:21:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/15/2023 03:28:18 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 03:19:11 PM
- Panacea Life Sciences Holdings, Inc. Chief Scientific Officer, Dr. James Baumgartner, is Featured on The Stock Day Podcast • InvestorsHub NewsWire • 07/18/2023 04:41:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2023 01:00:13 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM